Chagas' Heart Disease

Clinical Cardiology
23, 883-889
DOI: 10.1002/clc.4960231205

Citation Report

#	Article	IF	Citations
1	Clinical and epidemiological aspects of Chagas disease. Lancet Infectious Diseases, The, 2001, 1, 92-100.	4.6	729
2	Regional Diastolic Dysfunction in Chronic Chagas' Heart Disease. European Journal of Echocardiography, 2001, 2, 76-77.	2.3	1
3	Views on the autoimmunity hypothesis for Chagas disease pathogenesis. FEMS Immunology and Medical Microbiology, 2003, 37, 1-11.	2.7	42
5	Electrocardiographic findings in naturally acquired chagasic heart disease in nonhuman primates. Journal of Electrocardiology, 2003, 36, 155-160.	0.4	13
6	The trypanosomiases. Lancet, The, 2003, 362, 1469-1480.	6.3	673
7	Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in Trypanosoma cruzi-infected murine hearts: implications in chagasic myocarditis development. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1638, 106-120.	1.8	106
8	Captopril Ameliorates Myocarditis in Acute Experimental Chagas Disease. Circulation, 2003, 107, 2264-2269.	1.6	51
9	American trypanosomiasis (Chagas' disease): an unrecognised cause of stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 516-518.	0.9	69
10	Clinical management of chronic Chagas cardiomyopathy. Frontiers in Bioscience - Landmark, 2003, 8, e44-54.	3.0	99
11	Differing phagocytic function of monocytes and neutrophils in Chagas' cardiopathy according to the presence or absence of congestive heart failure. Revista Da Sociedade Brasileira De Medicina Tropical, 2004, 37, 447-453.	0.4	5
12	Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 645-649.	0.8	36
13	Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice. Infection and Immunity, 2004, 72, 46-53.	1.0	99
14	Utility of the Trypanosoma cruzi Sequence Database for Identification of Potential Vaccine Candidates by In Silico and In Vitro Screening. Infection and Immunity, 2004, 72, 6245-6254.	1.0	72
15	Impact of Long-Term Administration of Amiodarone on the Thyroid Function of Patients with Chagas' Disease. Thyroid, 2004, 14, 371-377.	2.4	13
16	Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radical Biology and Medicine, 2004, 37, 1821-1833.	1.3	116
17	Outcome of Right Ventricular Bifocal Pacing in Patients with Permanent Atrial Fibrillation and Severe Dilated Cardiomiopathy Due to Chagas Disease: Three Years of Follow-up. Journal of Interventional Cardiac Electrophysiology, 2004, 11, 193-198.	0.6	17
18	Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection. Parasitology Research, 2004, 92, 496-501.	0.6	32
19	Impaired mitochondrial respiratory chain and bioenergetics during chagasic cardiomyopathy development. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1689, 162-173.	1.8	92

#	Article	IF	Citations
20	Morphofunctional characteristics of the right ventricle in Chagas' dilated cardiomyopathy. International Journal of Cardiology, 2004, 94, 79-85.	0.8	56
21	Congestive heart failure in Latin America: the next epidemic. American Heart Journal, 2004, 147, 412-417.	1.2	81
23	Exercise Performance and Skeletal Muscles in Patients With Advanced Chagas Disease. Chest, 2004, 125, 1306-1314.	0.4	24
24	Efeitos da mudanÃ§a de modo de estimulaÃ§Ã£o ventricular para atrioventricular sobre a qualidade de vida em pacientes com cardiopatia chagÃ¡sica e bloqueio atrioventricular na troca eletiva do gerador de pulsos. Brazilian Journal of Cardiovascular Surgery, 2005, 20, 23.	0.2	1
25	An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. Anais Da Academia Brasileira De Ciencias, 2005, 77, 695-715.	0.3	70
26	Stroke in the Tropics. Seminars in Neurology, 2005, 25, 290-299.	0.5	8
27	Chagasic Cardiomyopathy Is Independently Associated With Ischemic Stroke in Chagas Disease. Stroke, 2005, 36, 965-970.	1.0	130
28	Chagas cardiomyopathy and ischemic stroke. Expert Review of Cardiovascular Therapy, 2006, 4, 119-130.	0.6	19
29	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	1.2	1,280
30	GuÃas de PrÃ¡ctica ClÃnica del ACC/AHA/ESC 2006 sobre el manejo de pacientes con arritmias ventriculares y la prevenciÃ³n de la muerte cardiaca sÃºbita.VersiÃ³n resumida. Revista Espanola De Cardiologia, 2006, 59, 1328.e1-1328.e51.	0.6	11
31	Congenital Chagas Disease. Perspectives in Medical Virology, 2006, 13, 223-258.	0.1	13
32	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Deathâ€"Executive Summary. Journal of the American College of Cardiology, 2006, 48, 1064-1108.	1.2	154
33	Toxic Side Effects of Drugs Used to Treat Chagasâ€™ Disease (American Trypanosomiasis). Human and Experimental Toxicology, 2006, 25, 471-479.	1.1	428
34	Amiodarone Has Intrinsic Anti-TrypanosomacruziActivity and Acts Synergistically with Posaconazoleâ€. Journal of Medicinal Chemistry, 2006, 49, 892-899.	2.9	162
35	Automatic Implantable Cardioverter-Defibrillators in Chagas' Heart Disease Patients with Malignant Ventricular Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 467-470.	0.5	46
36	The Sero-Prevalence of Antibodies to Trypanosoma cruzi in Latin American Refugees and Immigrants to Canada. Journal of Immigrant and Minority Health, 2006, 9, 43-47.	0.8	39
37	Confirmation of Chagas' cardiomyopathy following heart transplantation. Heart and Vessels, 2006, 21, 325-327.	0.5	4
38	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq1 1 0.784314 rgBT /Over o with the European Heart Rhythm Associat. European Heart Journal, 2006, 27, 2099-2140.	10	454

#	Article	IF	Citations
39	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484.	1.6	1,031
40	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq1 1 0.784314 rgBT /Overl Rhythm Association and the Heart R. Europace, 2006, 8, 746-837.	0.7	546
41	Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Research, 2006, 34, 4012-4024.	6.5	97
42	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Deathâ€"Executive Summary. Circulation, 2006, 114, 1088-1132.	1.6	85
43	Early nifurtimox-induced biochemical and ultrastructural alterations in rat heart. Human and Experimental Toxicology, 2007, 26, 781-788.	1.1	19
44	Evaluation and Treatment of Chagas Disease in the United States. JAMA - Journal of the American Medical Association, 2007, 298, 2171.	3.8	654
45	Nifurtimox nitroreductase activity in different cellular fractions from male rat pancreas. Biochemical and ultrastructural alterations. Life Sciences, 2007, 81, 144-152.	2.0	9
46	An update on the management of Chagas cardiomyopathy. Expert Review of Anti-Infective Therapy, 2007, 5, 727-743.	2.0	133
47	Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. International Journal of Antimicrobial Agents, 2007, 29, 733-737.	1.1	37
48	Cardiac Autonomic Modulation Evaluated by Heart Interval Variability is Unaltered but Subtly Widespread in the Indeterminate Chagas' Disease. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 772-780.	0.5	17
49	Left Ventricular Circulatory Support as Bridge to Heart Transplantation in Chagas' Disease Cardiomyopathy. Artificial Organs, 2007, 31, 253-258.	1.0	24
50	The Role of Circulatory Assistance and Heart Transplantation in Chagas' Disease Cardiomyopathy. Artificial Organs, 2007, 31, 245-248.	1.0	6
51	Implantable Cardioverterâ€Defibrillators in Patients with Chagas Heart Disease: Misperceptions, Many Questions and the Urgent Need for a Randomized Clinical Trial. Journal of Cardiovascular Electrophysiology, 2007, 18, 1241-1243.	0.8	39
52	Chagas disease in Texas: Recognizing the significance and implications of evidence in the literature. Social Science and Medicine, 2007, 65, 60-79.	1.8	61
53	Mechanisms of pathogenesis in Chagas disease. Acta Parasitologica, 2007, 52, 1-12.	0.4	32
54	Cardiac manifestations of parasitic infections part 1: Overview and immunopathogenesis. Clinical Cardiology, 2007, 30, 195-199.	0.7	12
55	Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment. Parasitology Research, 2008, 103, 663-669.	0.6	12
56	Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice. Microbes and Infection, 2008, 10, 1201-1209.	1.0	77

#	Article	IF	Citations
57	Invasive and Noninvasive Correlations of Bâ€Type Natriuretic Peptide in Patients With Heart Failure Due to Chagas Cardiomyopathy. Congestive Heart Failure, 2008, 14, 121-126.	2.0	13
58	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal, 2008, 156, 37-43.	1.2	183
59	Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. Vaccine, 2008, 26, 1999-2009.	1.7	51
60	Pivotal role for TGF-Î² in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine and Growth Factor Reviews, 2008, 19, 405-413.	3.2	71
61	Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart, 2008, 95, 524-534.	1.2	110
62	Chagas disease and the US blood supply. Current Opinion in Infectious Diseases, 2008, 21, 476-482.	1.3	126
63	Neglected Infections of Poverty in the United States of America. PLoS Neglected Tropical Diseases, 2008, 2, e256.	1.3	288
64	Other Infectious Diseases Related to Travel. , 2009, , 290-411.		12
66	Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 152-158.	0.8	146
67	Involvement of the Î²-adrenergic system in the cardiac chronic form of experimental Trypanosoma cruzi infection. Parasitology, 2009, 136, 905-918.	0.7	7
68	Aetiological treatment with itraconazole or ketoconazole in individuals withTrypanosoma cruzi/HIV co-infection. Annals of Tropical Medicine and Parasitology, 2009, 103, 471-476.	1.6	10
69	Pharmacological Inhibition of Transforming Growth Factor Î² Signaling Decreases Infection and Prevents Heart Damage in Acute Chagas' Disease. Antimicrobial Agents and Chemotherapy, 2009, 53, 4694-4701.	1.4	64
70	Oxidative Stress in Chagas Disease. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-8.	0.6	87
71	Evidence for an ATP-sensitive K+ channel in mitoplasts isolated from Trypanosoma cruzi and Crithidia fasciculata. International Journal for Parasitology, 2009, 39, 955-961.	1.3	16
72	pH-Dependent Mechanism of Nitric Oxide Release in Nitrophorins 2 and 4. Journal of Physical Chemistry B, 2009, 113, 1192-1201.	1.2	37
73	Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-Î³, TNF-Î±, and low IL-10 production during the acute infection phase. Veterinary Immunology and Immunopathology, 2009, 130, 43-52.	0.5	67
74	Differential distribution of Trypanosoma cruzi clones in human chronic chagasic cardiopathic and non-cardiopathic individuals. Acta Tropica, 2009, 109, 187-193.	0.9	19
75	Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: A prospective follow-up study. Journal of the Neurological Sciences, 2009, 278, 96-101.	0.3	49

#	Article	IF	Citations
76	Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Review of Anti-Infective Therapy, 2009, 7, 157-163.	2.0	282
77	American Trypanosomiasis. , 2009, , 1423-1450.		8
78	Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 122-135.	0.8	93
79	Ergosterol biosynthesis and drug development for Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 311-318.	0.8	178
80	Nanotechnological approaches against Chagas disease. Advanced Drug Delivery Reviews, 2010, 62, 576-588.	6.6	64
81	Chagas Cardiomyopathyâ€"Where Do We Stand After a Hundred Years?. Progress in Cardiovascular Diseases, 2010, 52, 300-316.	1.6	123
82	Molecular mechanisms of host cell invasion by Trypanosoma cruzi. Experimental Parasitology, 2010, 126, 283-291.	0.5	95
83	Clinical Phases and Forms of Chagas Disease. , 2010, , 709-741.		9
84	Chagas disease: Present status of pathogenic mechanisms and chemotherapy. Biological Research, 2010, 43, .	1.5	51
85	Natural infection of Trypanosoma cruzi in a dog with heart lesions: a case report from Malinalco, State of Mexico, Mexico. Research and Reports in Tropical Medicine, 2010, , 73.	2.8	0
86	Analysis of QRS loop in the Vectorcardiogram of patients with Chagas' disease. , 2010, 2010, 2561-4.		10
87	Cardiac Involvement with Parasitic Infections. Clinical Microbiology Reviews, 2010, 23, 324-349.	5.7	127
88	Chagas Cardiomyopathy in the Context of the Chronic Disease Transition. PLoS Neglected Tropical Diseases, 2010, 4, e688.	1.3	49
89	Mitochondrial Complex III Defects Contribute to Inefficient Respiration and ATP Synthesis in the Myocardium ofTrypanosoma cruziâ€"Infected Mice. Antioxidants and Redox Signaling, 2010, 12, 27-37.	2.5	44
90	Phenyl-Î±-tert-butyl-nitrone and Benzonidazole Treatment Controlled the Mitochondrial Oxidative Stress and Evolution of Cardiomyopathy in Chronic Chagasic Rats. Journal of the American College of Cardiology, 2010, 55, 2499-2508.	1.2	76
91	Chagas disease. Lancet, The, 2010, 375, 1388-1402.	6.3	1,906
92	Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica, 2010, 115, 55-68.	0.9	391
93	Trypanosoma cruzi and Chagas' Disease in the United States. Clinical Microbiology Reviews, 2011, 24, 655-681.	5.7	582

#	Article	IF	Citations
94	Neurodegeneration and Neuroregeneration in Chagas Disease. Advances in Parasitology, 2011, 76, 195-233.	1.4	27
95	Cavia porcellus as a Model for Experimental Infection by Trypanosoma cruzi. American Journal of Pathology, 2011, 179, 281-288.	1.9	19
98	Dysfunction of Diastolic [Ca2+] in Cardiomyocytes Isolated From Chagasic Patients. Revista Espanola De Cardiologia (English Ed), 2011, 64, 456-462.	0.4	6
99	Associating Chagasic Cardiomyopathy With Abnormal Diastolic Calcium Handling. Revista Espanola De Cardiologia (English Ed), 2011, 64, 451-452.	0.4	1
100	Pathogenesis and Pathology of Chagas' Chronic Myocarditis. , 2011, , .		0
101	Chagas' disease and Duffy antigen/receptor for chemokine (DARC): a mini-review. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2011, 17, 264-270.	0.8	1
102	Ablation of Ventricular Tachycardia Associated with Nonischemic Cardiomyopathies. , 2011, , 508-531.		2
103	The Neurology of Parasitic Diseases and Malaria. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 113-133.	0.4	8
104	Co-infection Trypanosoma cruzi/HIV: systematic review (1980 - 2010). Revista Da Sociedade Brasileira De Medicina Tropical, 2011, 44, 762-770.	0.4	87
105	Predictors of Mortality in Patients with Chagasâ€™ Cardiomyopathy and Ventricular Tachycardia Not Treated with Implantable Cardioverterâ€Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 54-62.	0.5	31
106	Prognostic Value of Exerciseâ€Induced Ventricular Arrhythmia in Chagasâ€™ Heart Disease. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1492-1497.	0.5	11
107	Antitrypanosomal Therapy for Chronic Chagas' Disease. New England Journal of Medicine, 2011, 364, 2527-2534.	13.9	234
108	Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers. BMC Infectious Diseases, 2011, 11, 206.	1.3	42
109	Amiodarone Inhibits Trypanosoma cruzi Infection and Promotes Cardiac Cell Recovery with Gap Junction and Cytoskeleton Reassembly In Vitro. Antimicrobial Agents and Chemotherapy, 2011, 55, 203-210.	1.4	32
110	Sialic Acids Attached to O-Glycans Modulate Voltage-gated Potassium Channel Gating. Journal of Biological Chemistry, 2011, 286, 4123-4132.	1.6	55
111	Crystal Structure of the Complex mAb 17.2 and the C-Terminal Region of Trypanosoma cruzi P2Î² Protein: Implications in Cross-Reactivity. PLoS Neglected Tropical Diseases, 2011, 5, e1375.	1.3	6
112	A Latin American Man with Palpitations, Dizziness, Episodes of Nonsustained Ventricular Tachycardia, and an Apical Aneurysm. PLoS Neglected Tropical Diseases, 2011, 5, e852.	1.3	6
113	Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease. PLoS Neglected Tropical Diseases, 2012, 6, e1696.	1.3	54

#	Article	IF	Citations
114	Chagas disease in the immunosuppressed host. Current Opinion in Infectious Diseases, 2012, 25, 450-457.	1.3	94
115	Risk of cardiovascular events associated with positive serology for Chagas: a systematic review. International Journal of Epidemiology, 2012, 41, 1356-1366.	0.9	6
116	Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome. Current Drug Targets, 2012, 13, 53-71.	1.0	19
117	Mortality prediction in Chagas heart disease. Expert Review of Cardiovascular Therapy, 2012, 10, 1173-1184.	0.6	40
118	American Trypanosomiasis (Chagas Disease). Infectious Disease Clinics of North America, 2012, 26, 275-291.	1.9	433
119	Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial. Trials, 2012, 13, 244.	0.7	15
121	Characterization of an Immunodominant Antigenic Epitope from Trypanosoma cruzi as a Biomarker of Chronic Chagas' Disease Pathology. Vaccine Journal, 2012, 19, 167-173.	3.2	21
122	FunÃ§Ãµes autonÃ´mica cardÃaca e mecÃ¢nica ventricular na cardiopatia chagÃ¡sica crÃ´nica assintomÃ¡tica. Arquivos Brasileiros De Cardiologia, 2012, 98, 111-119.	0.3	17
123	Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment. Current Infectious Disease Reports, 2012, 14, 263-274.	1.3	74
125	A Patient with Syncope. New England Journal of Medicine, 2013, 369, 966-972.	13.9	7
126	CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: Rationale and design of a randomized clinical trial. American Heart Journal, 2013, 166, 976-982.e4.	1.2	31
128	Trypomastigotes and amastigotes of Trypanosoma cruzi induce apoptosis and STAT3 activation in cardiomyocytes in vitro. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 653-663.	2.2	42
129	Chagas Disease: Global Epidemiology and Evolving Methods for Control. , 2013, , 139-167.		0
131	Cell Death and Serum Markers of Collagen Metabolism during Cardiac Remodeling in Cavia porcellus Experimentally Infected with Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2013, 7, e1996.	1.3	13
132	American Trypanosomiasis (Chagas disease). , 2013, , 725-738.		3
133	Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial. Trials, 2013, 14, 379.	0.7	10
134	Association of Heart Block with Uncommon Disease States. International Journal of Angiology, 2013, 22, 171-176.	0.2	4
135	Chagas Disease in Latin American Immigrants With Dilated Cardiomyopathy in New York City. Clinical Infectious Diseases, 2013, 57, e7-e7.	2.9	51

#	Article	IF	Citations
136	Pathogenesis of Chronic Chagasic Myocarditis. , 0, , .		1
137	Levels of circulating anti-muscarinic and anti-adrenergic antibodies and their effect on cardiac arrhythmias and dysautonomia in murine models of Chagas disease. Parasitology, 2014, 141, 1769-1778.	0.7	7
138	Absence of calcium-independent phospholipase A2Î²impairs platelet-activating factor production and inflammatory cell recruitment inTrypanosoma cruzi-infected endothelial cells. Physiological Reports, 2014, 2, e00196.	0.7	10
139	Clinical Reasoning: A 32-year-old woman with right-sided numbness and word-finding difficulties. Neurology, 2014, 83, e98-102.	1.5	0
140	Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opinion on Investigational Drugs, 2014, 23, 1225-1237.	1.9	61
141	Infectious causes of stroke. Lancet Infectious Diseases, The, 2014, 14, 869-880.	4.6	128
143	Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes. International Journal for Parasitology: Drugs and Drug Resistance, 2015, 5, 215-228.	1.4	39
144	Molecular mechanisms of myocarditis caused by Trypanosoma cruzi. Current Opinion in Infectious Diseases, 2015, 28, 246-252.	1.3	18
145	Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1224-1230.	0.6	38
146	Historical Perspectives on the Epidemiology of Human Chagas Disease in Texas and Recommendations for Enhanced Understanding of Clinical Chagas Disease in the Southern United States. PLoS Neglected Tropical Diseases, 2015, 9, e0003981.	1.3	53
147	Arrhythmias in Chagasic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 251-268.	0.7	34
148	Dynamic coupling between atrio-ventricular duration and RR-interval histogram phase-rectification analysis in chronic Chagas disease. , 2015, , .		1
149	Immunomodulatory properties and anti-apoptotic effects of zinc and melatonin in an experimental model of chronic Chagas disease. Immunobiology, 2015, 220, 626-633.	0.8	19
150	Sustained Domestic Vector Exposure Is Associated With Increased Chagas Cardiomyopathy Risk but Decreased Parasitemia and Congenital Transmission Risk Among Young Women in Bolivia. Clinical Infectious Diseases, 2015, 61, 918-926.	2.9	49
151	Between a bug and a hard place:Trypanosoma cruzigenetic diversity and the clinical outcomes of Chagas disease. Expert Review of Anti-Infective Therapy, 2015, 13, 995-1029.	2.0	146
152	Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review. Parasitology International, 2015, 64, 240-242.	0.6	27
153	Knowledge, attitudes, and practices of Texas hunters: a potentially high-risk population for exposure to the parasite that causes Chagas disease. Parasites and Vectors, 2015, 8, 197.	1.0	14
154	Chagas Disease. Neglected Tropical Diseases, 2015, , 45-71.	0.4	8

#	Article	IF	Citations
155	Chagas Disease: A Neglected Disease. , 2015, , 159-182.		0
156	Reactivation of Chagas Disease: Implications for Global Health. Trends in Parasitology, 2015, 31, 595-603.	1.5	37
157	Prevention of Cardiovascular Diseases. , 2015, , .		1
158	Gene-deleted live-attenuatedTrypanosoma cruziparasites as vaccines to protect against Chagas disease. Expert Review of Vaccines, 2015, 14, 681-697.	2.0	27
159	Recent Clinical Trials for the Etiological Treatment ofÂChronic Chagas Disease: Advances, Challenges andÂPerspectives. Journal of Eukaryotic Microbiology, 2015, 62, 149-156.	0.8	136
160	Circulating Serum Markers and QRS Scar Score in Chagas Cardiomyopathy. American Journal of Tropical Medicine and Hygiene, 2015, 92, 39-44.	0.6	32
161	Health Care Seeking Behavior of Persons with Acute Chagas Disease in Rural Argentina: A Qualitative View. Journal of Tropical Medicine, 2016, 2016, 1-8.	0.6	3
162	The Prevalence of Atrial Fibrillation and Conduction Abnormalities in Chagasâ€™ Disease: A Metaâ€Analysis. Journal of Cardiovascular Electrophysiology, 2016, 27, 161-169.	0.8	20
163	Mice with Genetic Deletion of Group VIA Phospholipase A ₂ Î² Exhibit Impaired Macrophage Function and Increased Parasite Load in Trypanosoma cruzi-Induced Myocarditis. Infection and Immunity, 2016, 84, 1137-1142.	1.0	13
164	A therapeutic nanoparticle vaccine againstTrypanosoma cruziin a BALB/c mouse model of Chagas disease. Human Vaccines and Immunotherapeutics, 2016, 12, 976-987.	1.4	52
165	Impact of vectorborne parasitic neglected tropical diseases on child health. Archives of Disease in Childhood, 2016, 101, 640-647.	1.0	9
166	The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii. Parasitology International, 2016, 65, 23-26.	0.6	14
167	The Prevalence of Trypanosoma cruzi, the Causal Agent of Chagas Disease, in Texas Rodent Populations. EcoHealth, 2017, 14, 130-143.	0.9	21
168	Challenges in the management of Chagas disease in Latin-American migrants in Europe. Clinical Microbiology and Infection, 2017, 23, 290-295.	2.8	61
169	Benznidazole treatment safety: the MÃ©decins Sans FrontiÃ¨res experience in a large cohort of Bolivian patients with Chagas' disease. Journal of Antimicrobial Chemotherapy, 2017, 72, 2596-2601.	1.3	31
170	Plasma concentrations of CCL3 and CCL4 in the cardiac and digestive clinical forms of chronic Chagas disease. Cytokine, 2017, 91, 51-56.	1.4	1
171	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Human Vaccines and Immunotherapeutics, 2017, 13, 621-633.	1.4	39
172	Infective Cardiomyopathy. , 2017, , .		0

#	Article	IF	Citations
173	Clinical phases and forms of Chagas disease. , 2017, , 653-686.		9
174	Chagas Cardiomyopathy Presenting as Symptomatic Bradycardia: An Underappreciated Emerging Public Health Problem in the United States. Case Reports in Cardiology, 2017, 2017, 1-5.	0.1	2
175	Canonical PI3Kî³ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. Nature Communications, 2018, 9, 1513.	5.8	19
176	The long road towards a safe and effective treatment of chronic Chagas disease. Lancet Infectious Diseases, The, 2018, 18, 363-365.	4.6	28
177	Chagas disease. Lancet, The, 2018, 391, 82-94.	6.3	945
178	Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). European Heart Journal Cardiovascular Imaging, 2018, 19, 459-460n.	0.5	48
179	Predictors of death in chronic Chagas cardiomyopathy patients with pacemaker. International Journal of Cardiology, 2018, 250, 260-265.	0.8	7
180	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.3	262
181	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
182	The effect of reinfection and mixed Trypanosoma cruzi infections on disease progression in mice. Acta Tropica, 2018, 178, 107-114.	0.9	20
183	Left Ventricular Scar and Prognosis in Chronic Chagas Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2567-2576.	1.2	46
184	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	1.2	991
185	Betulinic Acid Derivative BA5, Attenuates Inflammation and Fibrosis in Experimental Chronic Chagas Disease Cardiomyopathy by Inducing IL-10 and M2 Polarization. Frontiers in Immunology, 2019, 10, 1257.	2.2	10
186	The proteasome as a target for protozoan parasites. Expert Opinion on Therapeutic Targets, 2019, 23, 903-914.	1.5	32
187	Risk factors and select cardiac characteristics in dogs naturally infected with Trypanosoma cruzi presenting to a teaching hospital in Texas. Journal of Veterinary Internal Medicine, 2019, 33, 1695-1706.	0.6	22
188	A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Neglected Tropical Diseases, 2019, 13, e0007413.	1.3	40
189	Natural and synthetic quinoline molecules against tropical parasitic pathologies: an analysis of activity and structural evolution for developing new quinoline-based antiprotozoal agents. , 2019, , 87-164.		6
190	Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy. , 2019, , .		0

#	Article	IF	Citations
191	Chagas Disease in the United States: a Public Health Approach. Clinical Microbiology Reviews, 2019, 33, .	5.7	151
192	Reply to â€˜Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathiesâ€™. Nature Reviews Immunology, 2019, 19, 65-65.	10.6	0
193	Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0210156.	1.1	37
194	Chagas heart disease: A contemporary review. Journal of Nuclear Cardiology, 2020, 27, 445-451.	1.4	18
195	American Trypanosomiasis (Chagas Disease). , 2020, , 762-775.		10
196	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126779.	1.0	6
197	The Surgical Management of Parasitic Diseases. , 2020, , .		2
198	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 279-289.	0.2	1
199	Effect of Posaconazole in an in vitro model of cardiac fibrosis induced by Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2020, 238, 111283.	0.5	5
200	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De Cardiologia, 2020, 39, 279-289.	0.2	19
201	A CRISPR/Cas9-riboswitch-Based Method for Downregulation of Gene Expression in Trypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2020, 10, 68.	1.8	12
202	Selected cardiac abnormalities in Trypanosoma cruzi serologically positive, discordant, and negative working dogs along the Texas-Mexico border. BMC Veterinary Research, 2020, 16, 101.	0.7	12
203	Electrocardiographic and Echocardiographic Abnormalities in Chagas Disease: Findings in Residents of Rural Bolivian Communities Hyperendemic for Chagas Disease. Global Heart, 2015, 10, 159.	0.9	16
204	Polymorphism in the catalytic subunit of the PI3KÎ³ gene is associated with Trypanosoma cruzi-induced chronic chagasic cardiomyopathy. Infection, Genetics and Evolution, 2021, 88, 104671.	1.0	2
205	Chagas Disease: Coming to a Transplanted Patient Near You. , 2021, , 1293-1339.		0
206	High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA. PLoS Neglected Tropical Diseases, 2021, 15, e0009141.	1.3	12
207	The Impact of the Ca2+-Independent Phospholipase A2Î² (iPLA2Î²) on Immune Cells. Biomolecules, 2021, 11, 577.	1.8	1
208	The Selvester QRS score as an estimative of myocardial injury in acute chagasic patients from the Brazilian Amazon. BMC Infectious Diseases, 2021, 21, 396.	1.3	2

#	Article	IF	Citations
209	Diet Rich in Lard Promotes a Metabolic Environment Favorable to Trypanosoma cruzi Growth. Frontiers in Cardiovascular Medicine, 2021, 8, 667580.	1.1	4
210	Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technologyâ€™s stages. Expert Opinion on Therapeutic Patents, 2021, , 1-26.	2.4	2
211	Discovery of 1,3,4,5-tetrasubstituted pyrazoles as anti-trypanosomatid agents: Identification of alterations in flagellar structure of L. amazonensis. Bioorganic Chemistry, 2021, 114, 105082.	2.0	5
214	Durch Blut Ã¼bertragbare Infektionskrankheiten. , 2004, , 599-645.		1
215	Chagas Disease Knowledge and Risk Behaviors of the Homeless Population in Houston, TX. Journal of Racial and Ethnic Health Disparities, 2018, 5, 229-234.	1.8	5
216	Parasitic Infections of the Peripheral Nervous System. , 2005, , 2153-2176.		4
218	Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004407.	1.3	23
219	Polyclonal antibodies for the detection of Trypanosoma cruzi circulating antigens. PLoS Neglected Tropical Diseases, 2017, 11, e0006069.	1.3	8
220	Stroke Correlates in Chagasic and Non-Chagasic Cardiomyopathies. PLoS ONE, 2012, 7, e35116.	1.1	18
221	Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations. PLoS ONE, 2013, 8, e78367.	1.1	19
222	Oral Outbreak of Chagas Disease in Santa Catarina, Brazil: Experimental Evaluation of a Patientâ€™s Strain. PLoS ONE, 2015, 10, e0122566.	1.1	8
223	Chagas Cardiomyopathy: Usefulness of EKG and Echocardiogram in a Non-Endemic Country. PLoS ONE, 2016, 11, e0157597.	1.1	28
224	Chagas disease: an overview of diagnosis. Journal of Microbiology & Experimentation, 2018, 6, .	0.1	5
227	I Diretriz Latino-Americana para o DiagnÃ³stico e Tratamento da Cardiopatia ChagÃ¡sica. Arquivos Brasileiros De Cardiologia, 2011, 97, 01-48.	0.3	70
228	KomorovÃ© arytmie. Cor Et Vasa, 2011, 53, 53-77.	0.1	1
229	Blood smear analysis in babesiosis, ehrlichiosis, relapsing fever, malaria, and Chagas disease. Cleveland Clinic Journal of Medicine, 2008, 75, 521-530.	0.6	20
230	Case Report: High Mannose-Binding Lectin Serum Determined by MBL2 Genotype and Risk for Clinical Progression to Chagasic Cardiomyopathy: A Case Report of Three Patients. American Journal of Tropical Medicine and Hygiene, 2019, 100, 93-96.	0.6	1
231	CHRONIC CHAGASâ€™ DISEASE IN RHESUS MONKEYS (MACACA MULATTA): EVALUATION OF PARASITEMIA, SEROLOGY, ELECTROCARDIOGRAPHY, ECHOCARDIOGRAPHY, AND RADIOLOGY. American Journal of Tropical Medicine and Hygiene, 2003, 68, 683-691.	0.6	43

#	Article	IF	Citations
232	Chagas chronic cardiomyopathy: Report of two cases in Coahuila, Mexico. International Journal of Case Reports and Images, 2014, 5, 533.	0.0	2
233	Sustained ventricular tachycardia in structural heart disease. Cardiology Journal, 2015, 22, 12-24.	0.5	8
234	Electrocardiography as a Diagnostic Method for Chagas Disease in Patients and Experimental Models. , 0, , .		1
235	Carvedilol Enhances the Antioxidant Effect of Vitamins E and C in Chronic Chagas Heart Disease. Arquivos Brasileiros De Cardiologia, 2013, 101, 304-10.	0.3	18
236	Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009819.	1.3	18
237	Other Noteworthy Zoonotic Protozoa. World Class Parasites, 2003, , 165-183.	0.3	1
238	Antiinfektive Therapie. , 2004, , 75-207.		0
239	Congenital and Other Related Infectious Diseases of the Newborn. Perspectives in Medical Virology, 2006, , .	0.1	2
240	AdquisiciÃ³n y procesamiento de la seÃ±al ElectrocardiogrÃ¡fica, basado en la extracciÃ³n de potenciales intra-QRS e Ãndices de variabilidad del intervalo QT. IFMBE Proceedings, 2007, , 198-201.	0.2	0
241	Peculiarities of Acute Heart Failure Syndromes in Latin America and the Role of Chagasâ€™ Disease. , 2008, , 30-37.		0
242	Classification of Coronary Damage in Chronic Chagasic Patients. Studies in Computational Intelligence, 2010, , 461-477.	0.7	0
243	Passive Smoking and Infectious Disease: A Serious Hazard for Cardiovascular System. International Journal of Clinical Medicine, 2011, 02, 550-555.	0.1	1
244	Infectious Emergencies in Dermatology. , 2013, , 19-41.		0
245	AVALIAÃ‡ÃƒO CLÃNICA NA ATENÃ‡ÃƒO PRIMÃRIA E INFECTOLOGIA DOS PACIENTES COM DOENÃ‡A DE CHAGAS NA FORMA CRÃ”NICA. Revista Baiana SaÃºde PÃºblica, 0, 37, 7.	0.0	2
246	CoinfecÃ§Ã£o T. cruzi/HIV/Aids: revisÃ£o da literatura. , 2015, , 73-98.		0
247	13: Essential Oil-Based Nanomedicines against Trypanosomatides. , 2017, , 258-278.		0
248	Trypanosoma dionisii as an experimental model to study anti-Trypanosoma cruzi drugs: A comparative analysis with benznidazole, posaconazole and amiodarone. , 2018, 1, 014-023.		0
249	Chagas Disease: Coming to a Transplanted Patient Near You. , 2020, , 1-47.		0

#	Article	IF	Citations
250	Reproductive Outcomes in Rhesus Macaques (Macaca mulatta) with Naturally-acquired Trypanosoma cruzi Infection. Comparative Medicine, 2020, 70, 152-159.	0.4	4
251	Surgical Management of Parasitic Diseases Involving the Heart. , 2020, , 253-272.		1
253	Trypanosoma cruzi circulating in the southern region of the State of Mexico (Zumpahuacan) are pathogenic: a dog model. American Journal of Tropical Medicine and Hygiene, 2009, 81, 390-5.	0.6	15
260	Other Cardiomyopathies. , 0, , 718-732.		0
261	Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain. IJC Heart and Vasculature, 2022, 41, 101060.	0.6	0
262	Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure. Journal of Clinical Medicine, 2022, 11, 7262.	1.0	4
263	Successful Ablation of Ventricular Tachycardia in a Patient with Chagas Disease using Ethanol Ablation in the Coronary Venous System: A Case Report. HeartRhythm Case Reports, 2022, , .	0.2	0
264	Chagas disease-induced ventricular tachycardia: A case report. Global Cardiology Science & Practice, 2023, 2023, .	0.3	0
265	Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox. Journal of Pharmaceutical Sciences, 2023, 112, 1523-1538.	1.6	1
269	Breastfeeding and Maternal Parasitic Infections. , 2023, , 399-414.		0
271	Pathogenesis and Immune Response in T. cruzi Infection: Quest for Natural Compound-Based Drugs. , 2023, , 431-450.		0
272	Prediction Models of Sudden Death from Chronic Chagas Cardiomyopathy. IFMBE Proceedings, 2024, , 357-366.	0.2	0